DWIGHT SCHROEDER: Open Payments
NPI 1528047081 · CEDAR RAPIDS, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,589 in 183 payments from 15 companies in 2025. Trend: 2023 $1,996 · 2024 $2,384 · 2025 $2,589
Food & beverage: $2,589
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $355 |
| Otsuka America Pharmaceutical, Inc. | 17 | $340 |
| Neurocrine BioSciences, Inc. | 36 | $307 |
| Teva Pharmaceuticals USA, Inc. | 15 | $257 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $224 |
| Alkermes, Inc. | 16 | $221 |
| Supernus Pharmaceuticals, Inc. | 11 | $173 |
| Vanda Pharmaceuticals Inc. | 8 | $166 |
| E.R. Squibb & Sons, L.L.C. | 10 | $147 |
| Lundbeck LLC | 6 | $124 |
Products named: REXULTI, VRAYLAR, INGREZZA, CAPLYTA, ARISTADA, AUSTEDO XR, Qelbree, FANAPT.
Industry payments across IA — which companies pay providers there.
